In vivo cross-protection to African horse sickness Serotypes 5 and 9 after vaccination with Serotypes 8 and 6

Teichman, Beate F. von; Dungu, Baptiste; Smit, Theresa

doi:10.1016/j.vaccine.2010.06.105

Cited by 44 publications

(41 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In endemic areas, vaccination is performed by administration of combinations of representative live, attenuated strains of the different AHSV serotypes. Although serotypes 5 and 9 are excluded from vaccine formulations, these serotypes partially cross-reacts with serotype 8 and serotype 6, respectively (von Teichman et al, 2010). Despite their efficacy, AHS attenuated live virus vaccines are associated with several disadvantages.…”

Section: Introductionmentioning

confidence: 99%

Synthesis of empty african horse sickness virus particles

Maree

Putterill

et al. 2016

Virus Research

View full text Add to dashboard Cite

As a means to develop African horse sickness (AHS) vaccines that are safe and DIVA compliant, we investigated the synthesis of empty African horse sickness virus (AHSV) particles. The emphasis of this study was on the assembly of the major viral core (VP3 and VP7) and outer capsid proteins (VP2 and VP5) into architecturally complex, heteromultimeric nanosized particles. The production of fully assembled corelike particles (CLPs) was accomplished in vivo by baculovirus-mediated co-synthesis of VP3 and VP7. The two different outer capsid proteins were capable of associating independently of each other with preformed cores to yield partial virus-like particles (VLPs). Complete VLPs were synthesized, albeit with a low yield. Crystalline formation of AHSV VP7 trimers is thought to impede high-level CLP production. Consequently, we engineered and co-synthesized VP3 with a more hydrophilic mutant VP7, resulting in an increase in the turnover of CLPs.

show abstract

Section: Introductionmentioning

confidence: 99%

Synthesis of empty african horse sickness virus particles

Maree

Putterill

et al. 2016

Virus Research

View full text Add to dashboard Cite

show abstract

“…Efforts to prevent the catastrophic impact of AHS began soon after the determination of its viral etiology in 1900, at which time it was only the second animal virus ever described ( 8 , 9 ). Presently, a polyvalent, live, attenuated vaccine (LAV) against AHSV (AHSV-LAV), which is produced by Onderstepoort Biological Products (Pretoria, South Africa) and provides broad protection against all 9 AHSV types ( 10 ), is used widely in South Africa and adjacent countries. This vaccine is supplied in 2 vials, each containing different combinations of AHSV types: combination 1 is trivalent and contains types 1, 3, and 4, whereas combination 2 is tetravalent and contains types 2, 6, 7, and 8 ( 10 ).…”

mentioning

confidence: 99%

African Horse Sickness Caused by Genome Reassortment and Reversion to Virulence of Live, Attenuated Vaccine Viruses, South Africa, 2004–2014

Weyer¹,

Grewar²,

Burger³

et al. 2016

Emerg. Infect. Dis.

View full text Add to dashboard Cite

show abstract

“…Attempts for protection and prevention from African horse sickness diseases has started as early as 1930's; when a prophylactic vaccination was carried out in South Africa in 1933 using a bivalent live AHS vaccine. Other live attenuated vaccines were developed through years and currently there are commercially available for most AHSV serotypes [45,46,[48][49][50][51]. These vaccines are cheap and effective in producing a protective immunity following single inoculation, yet they have limitations; the biggest of which is the reassortment of the vaccine virus with wild-type virus strains in the mammalian host and/or insect [47,48,52].…”

Section: Discussionmentioning

confidence: 99%

“…Peptide vaccine have shown its preventive and therapeutic success in a considerable number of human and animal viruses and diseases including e.g, Influenza virus , Hepatitis B virus, Human Immune Deficiency virus (HIV), Ebola virus, cancer and others [53][54][55][56][57]. In this study we aimed to predict possible peptide vaccine for the African horse sickness virus and we targeted strain 6 out of 9 known strains for this virus [58] as the data we collected from the reference sequence alignment suggested to do.…”

Section: Discussionmentioning

confidence: 99%